Northwire Canada EditionTuesday, July 14, 2026
Northwire
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property

Ventripoint, FLH expand AI cardiac care to remote areas

VPT · Price

Executive Summary

  • Ventripoint Diagnostics Ltd. has entered into a strategic partnership with First Light Health (FLH) to deploy AI-powered cardiac diagnostics in Indigenous and remote communities across Canada.
  • The collaboration utilizes a hub-and-spoke model where local providers capture ultrasound scans using Ventripoint’s VMS+ system, which are then transmitted to specialists for interpretation, eliminating the need for patient travel.
  • First Light Health will serve as a key delivery partner, anchoring operations in Vancouver and extending services to remote communities in British Columbia, Yukon, Alberta, Manitoba, and New Brunswick.

Key Details

  • Partnership Structure: Hub-and-spoke model connecting central hubs with advanced cardiac capabilities to remote and Indigenous community sites.
  • Technology Deployed: Ventripoint’s VMS+ system, which converts standard 2-D echocardiograms into precise 3-D volumetric images with MRI-level accuracy.
  • Geographic Scope: Initial operations anchored in Vancouver, expanding to remote communities in British Columbia, Yukon, Alberta, Manitoba, and New Brunswick.
  • Target Demographic: Indigenous and remote communities facing barriers to specialist cardiac care, aiming to reduce travel distances, costs, and wait times.
  • Clinical Applications: The VMS+ system is used for diagnosing and monitoring congenital heart disease, heart failure, pulmonary hypertension, and chemotherapy-related cardiac complications.
  • Regulatory Status: VMS+ is approved for use in the United States, Canada, and Europe.
  • Strategic Goal: Expand the hub-and-spoke model across Canada and into international markets to ensure equitable access to accurate cardiac diagnostics.

Notable Quotes

  • Hugh MacNaught, CEO of Ventripoint: "Cardiovascular disease doesn't respect geography -- but too often, access to cardiac care does... We see the potential for this solution to be widely deployed -- from the Arctic to the Amazon. This is what scalable, equitable heart care looks like."
  • Dr. Ripenjot Rai, Medical Director, First Light Health: "At First Light Health, our mission is to help close long-standing gaps in access to care while advancing reconciliation through meaningful partnerships and responsible private enterprise... Collaborations like this help ensure patients in indigenous and remote communities receive timely, high-quality care while remaining connected to their communities."
Read the original news release →

More from Ventripoint Diagnostics Ltd